| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
178,600,000 |
| Market
Cap: |
246.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8901 - $1.85 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.4 |
| Insider 3/6 Months : 8 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precigen is a clinical-stage biopharmaceutical company improving gene and cell therapies. Co. is utilizing proprietary technology platforms to develop product candidates designed to diseases in its therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Co. is developing its clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. In addition, Co. has completed a Phase 1 study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
96,686 |
1,592,031 |
13,134,243 |
| Total Buy Value |
$0 |
$136,327 |
$2,615,293 |
$22,822,494 |
| Total People Bought |
0 |
1 |
4 |
8 |
| Total Buy Transactions |
0 |
1 |
6 |
12 |
| Total Shares Sold |
0 |
96,686 |
455,706 |
505,706 |
| Total Sell Value |
$0 |
$136,327 |
$650,097 |
$765,097 |
| Total People Sold |
0 |
1 |
6 |
6 |
| Total Sell Transactions |
0 |
1 |
21 |
22 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hassan Fred |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
57,061 |
|
- |
|
| Frank Steven |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
237,720 |
|
- |
|
| Kindler Jeffrey B |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
108,743 |
|
- |
|
| Shapiro Robert B |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
92,208 |
|
- |
|
| Gupta Vinita D |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
50,194 |
|
- |
|
| Alvarez Cesar L |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
150,071 |
|
- |
|
| Turley James S |
Director |
– • – |
2020-03-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,703 |
58,515 |
|
- |
|
| Kirk Randal J |
Executive Chairman |
• • • |
2020-02-28 |
4 |
A |
$4.39 |
$200,057 |
I/I |
45,571 |
22,730,215 |
|
- |
|
| Kirk Randal J |
Executive Chairman |
• • • |
2020-01-31 |
4 |
B |
$5.86 |
$34,999,999 |
I/I |
5,972,696 |
182,200 |
2.64 |
-21% |
|
| Kirk Randal J |
Executive Chairman |
• • • |
2020-01-31 |
4 |
A |
$6.02 |
$200,002 |
I/I |
33,223 |
18,528,842 |
|
- |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$31,571 |
D/D |
(5,416) |
148,888 |
|
-53% |
|
| Sabzevari Helen |
President and CEO |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$39,243 |
D/D |
(6,732) |
98,002 |
|
-53% |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$38,083 |
D/D |
(6,533) |
80,948 |
|
-53% |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$38,082 |
D/D |
(6,533) |
143,032 |
|
-53% |
|
| Bostick Thomas |
Chief Operating Officer |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$38,083 |
D/D |
(6,533) |
74,280 |
|
-53% |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2020-01-06 |
4 |
AS |
$5.83 |
$41,708 |
D/D |
(7,155) |
93,991 |
|
-53% |
|
| Reed Thomas D. |
Chief Science Officer |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,940 |
154,304 |
|
- |
|
| Sabzevari Helen |
President and CEO |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,667 |
104,734 |
|
- |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,940 |
87,481 |
|
- |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,940 |
149,565 |
|
- |
|
| Bostick Thomas |
Chief Operating Officer |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,940 |
80,813 |
|
- |
|
| Lehr Donald P. |
Chief Legal Officer |
• – – |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,940 |
101,146 |
|
- |
|
| Kirk Randal J |
Executive Chairman |
• • • |
2020-01-04 |
4 |
OE |
$0.00 |
$0 |
I/I |
3,443 |
18,495,619 |
|
- |
|
| Sterling Rick L. |
Chief Financial Officer |
• – – |
2020-01-03 |
4 |
AS |
$5.77 |
$20,564 |
D/D |
(3,564) |
130,625 |
|
-48% |
|
| Perez Jeffrey Thomas |
SVP, IP Affairs |
• – – |
2020-01-03 |
4 |
AS |
$5.77 |
$20,564 |
D/D |
(3,564) |
68,541 |
|
-48% |
|
689 Records found
|
|
Page 14 of 28 |
|
|
0.01 (0.72%) 
